Celularity (NASDAQ:CELU) Releases Quarterly Earnings Results

Celularity (NASDAQ:CELU) released its earnings results on Tuesday. The company reported $0.02 earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of $3.85 million during the quarter.

Celularity Trading Down 1.5%

Shares of CELU opened at $1.35 on Thursday. Celularity has a twelve month low of $0.56 and a twelve month high of $2.55. The stock’s 50 day moving average is $1.11 and its two-hundred day moving average is $1.01. The firm has a market capitalization of $39.08 million, a PE ratio of -0.41 and a beta of 0.79.

More Celularity News

Here are the key news stories impacting Celularity this week:

• Positive Sentiment: Board appointment adds strategic visibility: Naveen Jain, founder and CEO of Viome Life Sciences, has joined Celularity’s board. His experience in biotechnology, personalized health and consumer technology could support the company’s commercial strategy and investor profile. Celularity Announces Naveen Jain to Join Board of Directors
• Positive Sentiment: Potential Asia-Pacific revenue opportunity: Celularity highlighted Fontaine Vitale’s anticipated Q1 2027 opening in Bali, Indonesia. The strategic partnership could expand access to regenerative-medicine services in the region and create a future commercial channel, although revenue benefits are not yet realized. Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner
• Neutral Sentiment: Quarterly results showed positive reported EPS: Celularity reported $0.02 earnings per share and quarterly revenue of $3.85 million. The results provide a near-term positive data point, but the relatively small revenue base leaves questions about the sustainability and scale of growth. Celularity Inc. Reports Earnings Results
• Negative Sentiment: Convertible financing creates dilution concerns: Celularity announced a $25 million convertible-notes financing. The proceeds may improve liquidity and fund operations, but conversion into shares could dilute existing shareholders and increase financing risk. Celularity Announces Convertible Notes Financing and Board Changes
• Negative Sentiment: Board transition adds uncertainty: Director Geoffrey Ling’s resignation, effective September 24, alongside the board refresh may prompt investors to monitor governance and execution continuity. Geoffrey Ling Resigns from Celularity Board

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Celularity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Celularity

An institutional investor recently bought a new stake in Celularity stock. C V Starr & Co. Inc. purchased a new stake in Celularity, Inc. (NASDAQ:CELU) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 764,069 shares of the company’s stock, valued at approximately $1,582,000. Celularity makes up 0.8% of C V Starr & Co. Inc.’s holdings, making the stock its 4th biggest holding. C V Starr & Co. Inc. owned 2.64% of Celularity as of its most recent SEC filing. 19.02% of the stock is currently owned by institutional investors.

About Celularity

Celularity, Inc is a biotechnology company developing allogeneic cell therapies and biomaterial products derived from human placenta. The company’s research focuses on using placental cells and tissues to address unmet needs in oncology, immune-mediated diseases and regenerative medicine.

Celularity’s therapeutic pipeline has included CYNK-001, an off-the-shelf natural killer cell therapy being investigated for certain blood cancers, as well as other engineered and unmodified placental-derived cell programs.